These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 23722338)

  • 41. Ian Tomlinson.
    Tomlinson I
    Nat Rev Drug Discov; 2016 Mar; 15(3):154. PubMed ID: 26893183
    [No Abstract]   [Full Text] [Related]  

  • 42. Value networks identify innovation in 21st century pharmaceutical research.
    Edwards PJ
    Drug Discov Today; 2009 Jan; 14(1-2):68-77. PubMed ID: 18973823
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Developing pharmacogenetic evidence throughout clinical development.
    Burns DK
    Clin Pharmacol Ther; 2010 Dec; 88(6):867-70. PubMed ID: 20981004
    [TBL] [Abstract][Full Text] [Related]  

  • 44. How informatics can potentiate precompetitive open-source collaboration to jump-start drug discovery and development.
    Perakslis ED; Van Dam J; Szalma S
    Clin Pharmacol Ther; 2010 May; 87(5):614-6. PubMed ID: 20376001
    [No Abstract]   [Full Text] [Related]  

  • 45. Eyes on new product development.
    Novack GD
    J Ocul Pharmacol Ther; 2014 Jun; 30(5):371-2. PubMed ID: 24897062
    [No Abstract]   [Full Text] [Related]  

  • 46. Jay Bradner.
    Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
    [No Abstract]   [Full Text] [Related]  

  • 47. The role of discovery DMPK scientists in industry: where do we go from here?
    Moriwaki T
    Drug Metab Pharmacokinet; 2012; 27(2):169-70. PubMed ID: 22666880
    [No Abstract]   [Full Text] [Related]  

  • 48. Paul Brown. Interview by Asher Mullard.
    Brown P
    Nat Rev Drug Discov; 2011 Sep; 10(10):726. PubMed ID: 21959279
    [No Abstract]   [Full Text] [Related]  

  • 49. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
    Graul AI; Revel L; Rosa E; Cruces E
    Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sprinkling the pixie dust: reflections on innovation and innovators in medicinal chemistry and drug discovery.
    Macdonald SJF; Hatley RJD
    Drug Discov Today; 2020 Mar; 25(3):599-609. PubMed ID: 31981481
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Society for Biomolecular Sciences--15th Annual Conference. Bioassay and technology innovation: 15 years of shaping drug discovery. 26-30 April 2009, Lille, France.
    Napper AD
    IDrugs; 2009 Jun; 12(6):363-5. PubMed ID: 19517316
    [No Abstract]   [Full Text] [Related]  

  • 52. Joe selby. Interview by Asher Mullard.
    Selby J
    Nat Rev Drug Discov; 2011 Aug; 10(9):652. PubMed ID: 21878972
    [No Abstract]   [Full Text] [Related]  

  • 53. Restructurally sound.
    Borrell B
    Nat Med; 2011 May; 17(5):531-3. PubMed ID: 21546961
    [No Abstract]   [Full Text] [Related]  

  • 54. What matters most in commercial success: first-in-class or best-in-class?
    Schulze U; Ringel M
    Nat Rev Drug Discov; 2013 Jun; 12(6):419-20. PubMed ID: 23722339
    [No Abstract]   [Full Text] [Related]  

  • 55. Gigi Hirsch. Interview by Asher Mullard.
    Hirsch G
    Nat Rev Drug Discov; 2014 Jan; 13(1):14. PubMed ID: 24378793
    [No Abstract]   [Full Text] [Related]  

  • 56. Trial watch: Clinical trial cycle times continue to increase despite industry efforts.
    Martin L; Hutchens M; Hawkins C
    Nat Rev Drug Discov; 2017 Mar; 16(3):157. PubMed ID: 28184041
    [No Abstract]   [Full Text] [Related]  

  • 57. Open partnering of integrated drug discovery: continuing evolution of the pharmaceutical model.
    Hutchins S; Torphy T; Muller C
    Drug Discov Today; 2011 Apr; 16(7-8):281-3. PubMed ID: 21335101
    [No Abstract]   [Full Text] [Related]  

  • 58. Discontinued drugs in 2010: oncology drugs.
    Williams R
    Expert Opin Investig Drugs; 2011 Nov; 20(11):1479-96. PubMed ID: 21955127
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cancer charity sees success re-prioritizing industry's shelved compounds.
    Mullard A
    Nat Rev Drug Discov; 2014 May; 13(5):319-21. PubMed ID: 24781536
    [No Abstract]   [Full Text] [Related]  

  • 60. The Art of Virtualizing Pharma R&D.
    Schuhmacher A; Gassmann O; Kuss M; Hinder M
    Drug Discov Today; 2019 Nov; 24(11):2105-2107. PubMed ID: 31323393
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.